🔗 Share this article

An underground market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on communication apps, according to new investigations.

Experimental Treatment Gaining Popularity Online

Retatrutide, which is still in research studies, is being advertised by social media influencers for its supposed weight-reducing effects. Followers are encouraged to contact these accounts directly for supplier links, while also receiving promotional offers.

Active Trade on Messaging Platforms

Separately, a robust trade exists on messaging services, where groups with thousands of participants share “before and after” images, administration instructions and assertions of rapid UK delivery. Sellers promote the substance there before redirecting buyers to other platforms for purchases.

Understanding The Experimental Drug

Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the drug is being hailed digitally as the next Ozempic.

Medical Experts Voice Concerns

Nevertheless, doctors and pharmacists have warned that the sale of what remains an unapproved drug in the United Kingdom is worrisome and could lead to users administering substances of unknown origin.

Several professionals said the popularity for retatrutide could be connected to the rising price of licensed slimming treatments such as Mounjaro.

Regulatory Status and Implementation

Marketing retatrutide on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Several influencers try to sidestep the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and supply can still violate pharmaceutical, marketing, and consumer regulations, potentially leading to penalties, legal action or imprisonment.

Platform Response and Content Elimination

Based on the social media company, the platform has removed violative material and banned associated hashtags and search suggestions. The organization stated it was dedicated to maintaining the service safe and investing in strengthening enforcement strategies.

Online Trading Operations

Investigations also found groups with up to 9,000 participants selling retatrutide using Telegram's integrated discovery tool, which operates like a public directory. Typing “retatrutide” instantly displays channels with numerous of members, populated with photos of slimming results, positive reviews and detailed guides for mixing or injecting at residence.

Within moments of joining one community, a seller posted WhatsApp details, where most purchases take place. The seller sent an guidebook and guaranteed shipping within 48 hours. When questioned whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. Not one inquired about body mass, medical conditions or previous experience.

Product Information and Costs

Inside these communities, messages show dark colored parcels with Royal Mail labels, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at home with purified liquid, or pre-filled injectors typically priced at £160 for 20 milligrams. When asked how much time a injector should last, sellers give contradictory responses ranging from a several days to “depends on your body”.

Platform Moderation and Security Measures

A spokesperson for Telegram said it actively monitored dangerous content on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are administering materials they cannot confirm. Although the research behind retatrutide is sound, these digital products may not contain what they claim,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.

A medical professional of an online medical service connected the increase in interest to recent cost increases for authorized weight-loss medications such as Mounjaro. “With costs rising, patients are using social media. But fake treatments are highly risky. You can’t be certain what’s contained or whether the environment they were produced in was sterile,” she explained.

Her staff has already encountered individuals harmed by personal administration from unverified sources. “We understand the disappointment, but buying from Telegram or communication platforms is gambling with your well-being,” stated Wyllie. “These substances could be contaminated or improperly measured.”

Producer Statement

A spokesperson from Eli Lilly stated the substance was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this time no one can market [it] for personal consumption,” they explained, noting that any item “misleadingly claiming itself as a Lilly investigational substance not yet authorized … may subject users to possibly significant health risks”.